David R. Bauer
Lawyers
![](/sites/default/files/styles/teaser_headshot/public/lawyer-images/25898_drbauer.jpg?itok=Y1b0J_im)
Filters
TruArc Partners acquisition of Molded Devices
We advised TruArc Partners on the transaction
Intel $6 billion senior notes offering
The investment-grade notes were offered in five tranches, including a sustainability tranche
Gilead Sciences $405 million acquisition of MiroBio
We are advising Gilead Sciences on the transaction
Legend Biotech $403 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Revolution Medicines $264.5 million follow-on offering
The shares are listed on Nasdaq
Precigen sale of Trans Ova Genetics to URUS
We are advising Precigen on the transaction
Applied Therapeutics $30 million stock and warrants offering
The stock is listed on the Nasdaq Global Market
GSK $3.3 billion acquisition of Affinivax
We are advising GSK on the acquisition
PayPal $3 billion notes offering and concurrent tender offer
The investment-grade notes were issued in four tranches
Bausch + Lomb $630 million IPO
We are advising Bausch Health on the separation of its eye health business into a new public company, Bausch + Lomb